Literature DB >> 6269259

Pyridoxine supplementation during isoniazid therapy.

D E Snider.   

Abstract

Vitamin B6 (pyridoxine) supplementation during isoniazid (INH) therapy is necessary in some patients to prevent the development of peripheral neuropathy. In vivo pyridoxine is converted into coenzymes which play an essential role in the metabolism of protein, carbohydrates, fatty acids, and several other substances, including brain amines, INH apparently competitively inhibits the action of pyridoxine in these metabolic functions. The reported frequency of INH-induced neuropathy in various studies is reviewed and population groups at relatively high risk of developing this complication are identified. The routine use of pyridoxine supplementation to prevent peripheral neuropathy in high risk populations is recommended.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6269259     DOI: 10.1016/0041-3879(80)90038-0

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  19 in total

Review 1.  Tuberculosis: 9. Treatment.

Authors:  E Hershfield
Journal:  CMAJ       Date:  1999-08-24       Impact factor: 8.262

2.  "Pyridoxine supplementation with isonex - Is it necessary?"

Authors:  R K Maheshwari; B D Gupta
Journal:  Indian J Pediatr       Date:  1991-05       Impact factor: 1.967

3.  Chemoprophylaxis against tuberculosis.

Authors:  D L Coleman; G Slutkin
Journal:  West J Med       Date:  1984-01

4.  A stepwise guide for treating tuberculosis.

Authors:  S C Deresinski
Journal:  West J Med       Date:  1984-10

5.  Adverse effects of antituberculosis drugs.

Authors:  D J Girling
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

Review 6.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705

7.  A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis.

Authors:  Eduardo Villamor; Ferdinand Mugusi; Willy Urassa; Ronald J Bosch; Elmar Saathoff; Kenji Matsumoto; Simin N Meydani; Wafaie W Fawzi
Journal:  J Infect Dis       Date:  2008-06-01       Impact factor: 5.226

8.  Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.

Authors:  April C Pettit; James Bethel; Yael Hirsch-Moverman; Paul W Colson; Timothy R Sterling
Journal:  J Infect       Date:  2013-07-08       Impact factor: 6.072

9.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

Review 10.  Avoidance and management of adverse reactions to antituberculosis drugs.

Authors:  A M Patel; J McKeon
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.